Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phenytoin: pharmacokinetics and bioavailability.

R Gugler, C V Manion, D L Azarnoff

    Clinical Pharmacology and Therapeutics
    |February 1, 1976
    PubMed
    Summary

    This study found that phenytoin

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Information needs of patients with prostate cancer. Pronounced differences between individuals after diagnosis of localised prostate carcinoma].

    Der Urologe. Ausg. A·2011
    Same author

    [A young diabetic with small-nodule liver cirrhosis, high transferrin saturation and negative HFE test].

    Deutsche medizinische Wochenschrift (1946)·2005
    Same author

    HJV gene mutations in European patients with juvenile hemochromatosis.

    Clinical genetics·2005
    Same author

    [Topic Complex IV: Erosive reflux disease (ERD)].

    Zeitschrift fur Gastroenterologie·2005
    Same author

    [The elderly patient with esophageal and gastric disease].

    Praxis·2005
    Same author

    Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection.

    Journal of viral hepatitis·2004

    Area of Science:

    • Pharmacology
    • Clinical Pharmacy

    Background:

    • Phenytoin is an anticonvulsant medication.
    • Understanding its pharmacokinetic profile is crucial for effective therapeutic management.

    Purpose of the Study:

    • To investigate the pharmacokinetics of phenytoin following single and multiple oral and intravenous doses.
    • To assess the absolute bioavailability of an oral phenytoin formulation.

    Main Methods:

    • A pharmacokinetic study was conducted in 6 healthy volunteers.
    • Single oral and intravenous doses of 300 mg phenytoin were administered.
    • 14 daily oral doses of 300 mg phenytoin were administered.

    Main Results:

    • The plasma elimination half-life (t1/2) of phenytoin was consistent between single intravenous and oral doses.
    • A statistically significant increase in t1/2 was observed after chronic oral administration.
    • Absolute bioavailability of the oral formulation varied, with higher average bioavailability noted when compared to intravenous dosing.

    Conclusions:

    • Variability in phenytoin bioavailability and elimination complicates accurate prediction of steady-state plasma concentrations.
    • Regular monitoring of plasma phenytoin levels is recommended for optimal patient management.

    Related Experiment Videos